MedTrace Logo

A Study of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus

NCT06535412 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 218

Last updated 2026-06-29

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of IMC-002 and IMM0306S in the treatment of active SLE.

Conditions

Interventions

DRUG

IMC-002 + SOC

intravenous injection of 0.8mg/kg、1.2mg/kg and1.6mg/kg

DRUG

Placebo + SOC

intravenous or subcutaneous injection of Placebo

DRUG

IMM0306S + SOC

subcutaneous injection of 2.0 mg/kg，4.0 mg/kg and 6.0mg/kg

Sponsors & Collaborators

  • ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-10
Primary Completion
2028-12-17
Completion
2028-12-17

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06535412 on ClinicalTrials.gov